- βMedicare enrollees are capped at $35/month for all covered insulin types regardless of retail price
- βMany private insurers have voluntarily adopted similar $35 caps β always verify your specific plan
- βIf overcharged at the pharmacy, you are legally entitled to a retroactive billing correction
What Is the $35 Insulin Cap?
If you've been struggling with the cost of insulin, the $35 monthly cap is one of the most significant pieces of relief legislation in recent diabetes history. Signed into law as part of the Inflation Reduction Act of 2022, this rule limits out-of-pocket insulin costs for Medicare beneficiaries to $35 per month β regardless of the retail price of the insulin itself.
For context, some insulin formulations retail for over $300 per vial. The $35 cap means that what you pay at the pharmacy bears no relationship to that sticker price β your cost is capped, period.
Who Is Covered by the $35 Rule?
It's critical to understand that the federal $35 cap currently applies specifically to people enrolled in Medicare β including Medicare Part D prescription drug plans and Medicare Advantage plans that include drug coverage. This went into effect on January 1, 2023.
- Medicare Part D enrollees: Fully covered by the $35 monthly cap
- Medicare Advantage (Part C) with drug coverage: Also covered
- Private insurance holders: Not federally mandated, though many states and insurers have voluntarily adopted similar caps
- Uninsured individuals: Not covered under the federal rule
What About Private Insurance?
If you have employer-sponsored or marketplace insurance, the federal $35 cap does not automatically apply. However, this is a rapidly evolving landscape. Many major insurers β including Cigna, Aetna, and UnitedHealthcare β have voluntarily capped insulin costs at $35 for their members. Always check your specific plan's Summary of Benefits or call your insurer directly to confirm your insulin cost-sharing terms.
Which Insulins Are Covered?
The cap applies to all insulin types covered under your Medicare plan, including:
- Rapid-acting insulins (such as Humalog, NovoLog, Fiasp)
- Long-acting insulins (such as Lantus, Basaglar, Tresiba)
- Intermediate-acting and premixed insulins
The insulin must be FDA-approved and listed on your plan's formulary. If your specific brand isn't covered, your prescriber can work with you on a formulary alternative.
How to Make Sure You're Paying the Capped Price
Even with the law in place, some pharmacies have inadvertently charged more. Here's how to protect yourself:
- Always ask the pharmacist to confirm your copay before paying
- Bring documentation of your Medicare coverage
- If overcharged, request a retroactive adjustment β plans are required to correct billing errors
- Use Medicare's online Plan Finder tool to compare drug plans at enrollment
Additional Savings Strategies
The $35 cap is a powerful tool, but it isn't the only one available. Manufacturer patient assistance programs, state pharmaceutical assistance programs, and insulin discount cards can all help bridge gaps β especially for those not yet on Medicare. Resources like mdsdiabetes.com offer guidance on navigating insulin affordability options, from insurance questions to supply cost comparisons, so you're never making these decisions alone.
Looking Ahead
Advocacy groups continue to push for a universal $35 cap covering all Americans regardless of insurance status. Staying informed and engaged with diabetes policy news ensures you can act quickly when new benefits become available.